OLAPARIB for Transitional cell carcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

There are 5 adverse event reports in the FDA FAERS database where OLAPARIB was used for Transitional cell carcinoma.

Most Reported Side Effects for OLAPARIB

Side Effect	Reports	%	Deaths	Hosp.
Death	4,378	24.0%	4,377	104
Malignant neoplasm progression	1,862	10.2%	368	180
Nausea	1,582	8.7%	129	301
Anaemia	1,455	8.0%	205	469
Fatigue	1,437	7.9%	101	241
Off label use	777	4.3%	212	126
Vomiting	642	3.5%	82	187
Drug ineffective	563	3.1%	67	67
Diarrhoea	514	2.8%	60	131
Asthenia	491	2.7%	51	132
Myelodysplastic syndrome	466	2.6%	114	136
Decreased appetite	450	2.5%	51	121
Disease progression	423	2.3%	56	37
Neuropathy peripheral	411	2.3%	13	38
Haemoglobin decreased	390	2.1%	34	117